Pitfalls in the measurement of circulating vascular endothelial growth factor

Clinical Chemistry

Volumn 47, Issue 4, 2001, Pages 617-623

  Jelkmann, W ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; VASCULOTROPIN;

ANGIOGENESIS; BLOOD CLOTTING; CANCER; CARDIOVASCULAR DISEASE; HUMAN; HYPOXIA; IMMUNOASSAY; INFLAMMATION; LEUKOCYTE; MEASUREMENT; PROTEIN ANALYSIS; SHORT SURVEY; THROMBOCYTE;

EID: 0035060498     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/47.4.617     Document Type: Short Survey

References (63)

1. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
2. The biology of vascular endothelial growth factor
3. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
4. Vascular endothelial growth factor (VEGF) and its receptors
5. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors
6. Hypoxia and interleukin-1β stimulate vascular endothelial growth factor production in human proximal tubular cells
7. Role of vascular endothelial growth factor in the regulation of angiogenesis
8. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?
9. Vascular endothelial growth factors VEGF-B and VEGF-C
10. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency
11. Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins
12. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus
13. Sensitive chemiluminescence enzyme immunoassay for vascular endothelial growth factor/vascular permeability factor in human serum
14. Vascular endothelial growth factor and its receptor, Flt-1, in smokers and non-smokers
15. A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor 165 in human plasma
16. Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor-tissue homogenates
17. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: Implications for measurement of circulating VEGF levels in clinical disease
18. Cytokine assays in human sera and tissues
19. Analytical performances of commercial ELISA-kits for IL-2, IL-6 and TNF-α. A WHO study
20. Vascular endothelial growth factor is inactivated by binding to α2-macroglobulin and the binding is inhibited by heparin
21. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR
22. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation
23. Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1
24. The total cytokine concept: The influence of soluble receptors in the cytokine measurement
25. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: Relationship to endothelial dysfunction and laser treatment
26. Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA
27. Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: Relevance to ovarian hyperstimulation syndrome and polycystic ovaries
28. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids
29. Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration
30. Platelet: Transporter of vascular endothelial growth factor
31. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology
32. In vitro release of vascular endothelial growth factor during platelet aggregation
33. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer
34. Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: Survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells
35. Soluble vascular endothelial growth factor in various blood transfusion components
36. Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking
37. Increased plasma vascular endothelial growth factor among patients with chronic venous disease
38. Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen
39. Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver metastasis vascularity and volume
40. Vascular endothelial growth factor (VEGF) and melanoma. N-Acetylcysteine downregulates VEGF production in vitro
41. Serum vascular endothelial growth factor (VEGF), a prognostic indicator in sarcoma and carcinoma patients
42. Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy
43. Activated human neutrophils express vascular endothelial growth factor (VEGF)
44. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?
45. Maternal serum vascular endothelial growth factor during early pregnancy
46. Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre-eclampsia
47. Vascular endothelial growth factor is increased in patients with preeclampsia
48. Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia
49. Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program
50. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome
51. Plasma vascular endothelial growth factor in acute mountain sickness
52. Increase in immune activation, vascular endothelial growth factor and erythropoietin after an ultramarathon run at moderate altitude
53. Vascular endothelial growth factor and basic fibroblast growth factor in children with cyanotic congenital heart disease
54. Serum levels of VEGF and basic FGF in the subacute phase of myocardial infarction
55. Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients
56. Placenta growth factor (PIGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid
57. Growth factors in POEMS syndrome: Evidence for a marked increase in circulating vascular endothelial growth factor
58. Vascular endothelial growth factor in acute Kawasaki disease
59. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients
60. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: Which is the optimal specimen?
61. Elevated levels of angiogenic cytokines in the plasma of cancer patients
62. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma
63. Plasma levels of vascular endothelial growth factor (VEGF) in haematological cancers